Skip to main content

Table 11 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the Barthel Index, for the subgroup in Switzerland

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
Barthel Index
 Improved 0.41 0.79 0.38 (0.04 to 0.71) 1.63* 4 100
 No change 0.93 0.89 − 0.03 (− 0.10 to 0.02) − 0.23 39 15
 Worsened 0.84 0.70 − 0.13 (− 0.30 to 0.02) − 0.54 12 17
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
Barthel Index
 Improved 0.40 0.73 0.32 (0.01 to 0.63) 1.49 4 100
 No change 0.91 0.90 − 0.01 (− 0.05 to 0.02) − 0.11 39 15
 Worsened 0.78 0.71 − 0.06 (− 0.20 to 0.07) − 0.28 12 33
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
  2. *p < 0.05
\